Navigating Disparities Amongst Treatment Guidelines: Management of Initial and Recurrent Clostridium difficile Infection – Module 2

Severe-complicated and Recurrent CDI

Sponsored by the Academy for Continued Healthcare Learning.

This activity is supported by an independent education grant from Cubist Pharmaceuticals.

Scroll to the Bottom of this Information to Begin this Course

Release date: December 9, 2014

Valid through: December 9, 2015

Specialty: Gastroenterology, Infectious disease

Topic: Clostridium difficile Infection

Estimated Time to Complete Activity: 30 minutes

Target Audience

This educational activity is designed for gastroenterologists and other healthcare professionals treating Clostridium difficile infections.

Program Overview

The epidemiology and incidence of hospital- and community-acquired CDI have changed over the past decade. As such, clinicians must be familiar with evolving diagnostic parameters, guidelines, and treatment approaches to reduce complications and improve clinical outcomes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the diagnosis of C. diff infection and assessment of disease severity
  • Compare and contrast clinical outcomes with pharmacotherapies for C. diff infection
  • Evaluate therapeutic interventions for the management of severe-complicated and recurrent C. diff infection

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Faculty

Carl V. Crawford, MD (Presenting Faculty)
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
New York Presbyterian – Weill Cornell Medical Center
New York, New York

Darrell S. Pardi, MD (Chair)
Professor of Medicine
Inflammatory Bowel Disease Clinic
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine
Rochester, Minnesota

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.

The following financial relationships have been provided:

Carl V. Crawford, MD (Presenting Faculty)

  • Advisory Panel: Cubist Pharmaceuticals
  • Consultant: Cubist Pharmaceuticals and EnteraHealth
  • Speakers' Bureau: Cubist Pharmaceuticals, EnteraHealth and Salix Pharmaceuticals
  • Research Support: Cubist Pharmaceuticals, Sanofi Pasteur, Summit Pharmaceuticals, and Rebiotix Inc.

Darrell S. Pardi, MD (Chair)

  • Advisory Panel: Cubist Pharmaceuticals

Staff and Reviewer Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Instructions for Participation and Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online webcast and complete the post-test and evaluation form. To receive credit, 65% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Media

Internet

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. This activity requires: Adobe Flash Player

Disclosure of Unlabeled Use

Discussion of off-label, investigational, or experimental drug/device use: Use of metronidazole, intravenous immunoglobulin, rifaximin, tigecycline, and linezolid for treatment of C. diff infections.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Inquires may be directed to ACHL at (877) 444-8435, ext. 203.